Richard E. Royal

Maine Medical Center — United States

Medicine · Health Sciences

52h-index19.5kcitations182works0.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Intraperitoneal and Appendiceal Malignancies(54), Immunotherapy and Immune Responses(43), CAR-T cell therapy research(37), Cancer Immunotherapy and Biomarkers(36), Cutaneous Melanoma Detection and Management(29)

Publications181 total

Perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy following neoadjuvant systemic therapy for high-volume peritoneal mesothelioma
Surgical Oncology Insight·2025Open Access
Elizabeth Anne Leece, BVSc, Cert VA, Dip ECVAA, MRCVS (1970–2025)
Veterinary Anaesthesia and Analgesia·2025Open Access
ASO Visual Abstract: Clinicopathologic and Molecular Characteristics of High-Grade Appendiceal Mucinous Neoplasms
Annals of Surgical Oncology·2025
Just when things are going smoothly: Encapsulated sclerosing peritonitis after HIPEC
European Journal of Surgical Oncology·2025
Clinicopathologic and Molecular Characteristics of High-Grade Appendiceal Mucinous Neoplasms
Annals of Surgical Oncology·2025· 1 citedOpen Access
Corrigendum to “Prognostic Model for Patient Survival in Primary Anorectal Mucosal Melanoma: Stage at Presentation Determines Relevance of Histopathologic Features” [Modern Pathology 33 (2020) 496–513]
Modern Pathology·2025
Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit
Annals of Surgical Oncology·2023· 10 citedOpen Access
Decreasing Environmental Operating Room Chemotherapy Levels Following Heated Intraperitoneal Chemotherapy (HIPEC) Through Implementation of Standard Protocols
Annals of Surgical Oncology·2023
Data from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
2023Open Access
Supplementary Protocol from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
2023Open Access
Supplementary Protocol from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
2023Open Access
Supplementary Data from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
2023Open Access
Data from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
2023Open Access
Supplementary Data from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
2023Open Access
Supplementary Table 3 - 4 from Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients
2023Open Access
Data from Circulating Tumor Cells and Early Relapse in Node-positive Melanoma
2023Open Access
Supplementary Figures 1 - 7 from Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients
2023Open Access
Supplementary Table 2 from Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients
2023Open Access
Supplementary Table 1 from Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients
2023Open Access
Supplementary Table 5 from Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients
2023Open Access
page 1 of 10Next →

Frequent Co-authors

Steven A. Rosenberg(20), Udai S. Kammula(17), Richard M. Sherry(16), Marybeth S. Hughes(15), James Chih‐Hsin Yang(14), Suzanne L. Topalian(11), Merrick I. Ross(11), Janice N. Cormier(11), Jeffrey E. Gershenwald(11), Anthony Lucci(10), Jeffrey E. Lee(10), Catherine Lévy(8), Keith F. Fournier(8), Nicholas P. Restifo(7), Sharon Mavroukakis(7), Donald E. White(7), Seth M. Steinberg(7), Patrick Hwu(6), Michael Yellin(5), Michael A. Davies(5)